Replies to post #17195 on MMRGlobal, Inc. (fka MMRF)

[RUBY1100]

The Company plans on expanding its Boards of Advisors to include biotech financing and licensing expertise to help maximize the value of these assets. MMR understands that the samples and data may be of value in a possible successful reinterpretation of the pre-merger Favrille vaccine trials and that the IP may also unlock ways to create other "custom-made" cancer vaccines and be valuable in discovering additional opportunities in cancer research. The Company hopes to enter into additional licensing agreements with biopharmaceutical companies, academic institutions, research organizations and others regarding the use of its assets.

[EZ2]

As a result of that investigation, it was determined that there was no guarantee that the samples and data would be used exclusively and only in the interest of science and therefore MMR shareholders should benefit from these assets in the event and to the extent they generate revenue."

[legolas233]

Their seems te be alot of "undiscovered" value in the Biotech Assets...